Ghent University Academic Bibliography

Advanced

Investigational approaches for mesothelioma

Veerle Surmont UGent, Eric RE Van Thiel, Karim Vermaelen UGent and Jan Van Meerbeeck UGent (2011) FRONTIERS IN ONCOLOGY. 1.
abstract
Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor with a poor prognosis. In view of the poor survival benefit from first-line chemotherapy and the lack of subsequent effective treatment options, there is a strong need for the development of more effective treatment approaches for patients with MPM. This review will provide a comprehensive state of the art of new investigational approaches for mesothelioma. In an introductory section, the etiology, epidemiology, natural history, and standard of care treatment for MPM will be discussed. This review provide an update of the major clinical trials that impact mesothelioma treatment, discuss the impact of novel therapeutics, and provide perspective on where the clinical research in mesothelioma is moving. The evidence was collected by a systematic analysis of the literature (2000–2011) using the databases Medline (National Library of Medicine, USA), Embase (Elsevier, Netherlands), Cochrane Library (Great Britain), National Guideline Clearinghouse (USA), HTA Database (International Network of Agencies for Health Technology Assessment – INAHTA), NIH database (USA), International Pleural Mesothelioma Program – WHOLIS (WHO Database), with the following keywords and filters: mesothelioma, guidelines, treatment, surgery, chemotherapy, radiotherapy, review, investigational, drugs. Currently different targeted therapies and biologicals are under investigation for MPM. It is important that the molecular biologic research should first focus on mesothelioma-specific pathways and biomarkers in order to have more effective treatment options for this disease. The use of array technology will be certainly an implicit gain in the identification of new potential prognostic or biomarkers or important pathways in the MPM pathogenesis. Probably a central mesothelioma virtual tissue bank may contribute to the ultimate goal to identify druggable targets and to develop personalized treatment for the MPM patients.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
targeted therapy, chemotherapy, mesothelioma
journal title
FRONTIERS IN ONCOLOGY
Front. Oncol.
volume
1
article_number
22
pages
15 pages
ISSN
2234-943X
DOI
10.3389/fonc.2011.00022
language
English
UGent publication?
yes
classification
A2
additional info
published in specialty section: Frontiers in Thoracic Oncology
copyright statement
I have retained and own the full copyright for this publication
id
2044144
handle
http://hdl.handle.net/1854/LU-2044144
date created
2012-02-24 13:54:26
date last changed
2012-03-06 15:01:56
@article{2044144,
  abstract     = {Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor with a poor prognosis. In view of the poor survival benefit from first-line chemotherapy and the lack of subsequent effective treatment options, there is a strong need for the development of more effective treatment approaches for patients with MPM. This review will provide a comprehensive state of the art of new investigational approaches for mesothelioma. In an introductory section, the etiology, epidemiology, natural history, and standard of care treatment for MPM will be discussed. This review provide an update of the major clinical trials that impact mesothelioma treatment, discuss the impact of novel therapeutics, and provide perspective on where the clinical research in mesothelioma is moving. The evidence was collected by a systematic analysis of the literature (2000--2011) using the databases Medline (National Library of Medicine, USA), Embase (Elsevier, Netherlands), Cochrane Library (Great Britain), National Guideline Clearinghouse (USA), HTA Database (International Network of Agencies for Health Technology Assessment -- INAHTA), NIH database (USA), International Pleural Mesothelioma Program -- WHOLIS (WHO Database), with the following keywords and filters: mesothelioma, guidelines, treatment, surgery, chemotherapy, radiotherapy, review, investigational, drugs. Currently different targeted therapies and biologicals are under investigation for MPM. It is important that the molecular biologic research should first focus on mesothelioma-specific pathways and biomarkers in order to have more effective treatment options for this disease. The use of array technology will be certainly an implicit gain in the identification of new potential prognostic or biomarkers or important pathways in the MPM pathogenesis. Probably a central mesothelioma virtual tissue bank may contribute to the ultimate goal to identify druggable targets and to develop personalized treatment for the MPM patients.},
  articleno    = {22},
  author       = {Surmont, Veerle and Van Thiel, Eric RE  and Vermaelen, Karim and Van Meerbeeck, Jan},
  issn         = {2234-943X},
  journal      = {FRONTIERS IN ONCOLOGY},
  keyword      = {targeted therapy,chemotherapy,mesothelioma},
  language     = {eng},
  pages        = {15},
  title        = {Investigational approaches for mesothelioma},
  url          = {http://dx.doi.org/10.3389/fonc.2011.00022},
  volume       = {1},
  year         = {2011},
}

Chicago
SURMONT, VEERLE, Eric RE Van Thiel, Karim Vermaelen, and Jan Van Meerbeeck. 2011. “Investigational Approaches for Mesothelioma.” Frontiers in Oncology 1.
APA
SURMONT, VEERLE, Van Thiel, E. R., Vermaelen, K., & Van Meerbeeck, J. (2011). Investigational approaches for mesothelioma. FRONTIERS IN ONCOLOGY, 1.
Vancouver
1.
SURMONT V, Van Thiel ER, Vermaelen K, Van Meerbeeck J. Investigational approaches for mesothelioma. FRONTIERS IN ONCOLOGY. 2011;1.
MLA
SURMONT, VEERLE, Eric RE Van Thiel, Karim Vermaelen, et al. “Investigational Approaches for Mesothelioma.” FRONTIERS IN ONCOLOGY 1 (2011): n. pag. Print.